Eli Lilly and Co  

(Public, NYSE:LLY)   Watch this stock  
Find more results for LLY
64.68
0.00 (0.00%)
After Hours: 64.68 0.00 (0.00%)
Oct 22, 6:46PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 64.58 - 65.30
52 week 48.88 - 67.14
Open 64.59
Vol / Avg. 4.30M/4.12M
Mkt cap 72.27B
P/E 20.59
Div/yield 0.49/3.03
EPS 3.14
Shares 1.12B
Beta 0.43
Inst. own 76%
Nov 12, 2014
Eli Lilly and Co at Credit Suisse Healthcare Conference - 12:30PM EST - Add to calendar
Oct 23, 2014
Q3 2014 Eli Lilly and Co Earnings Release - 9:30AM EDT - Add to calendar
Oct 23, 2014
Q3 2014 Eli Lilly and Co Earnings Conference Call - 9:00AM EDT - Add to calendar
Sep 17, 2014
Eli Lilly and Co at Morningstar's Management Behind the Moat Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 14.86% 20.27%
Operating margin 17.96% 23.24%
EBITD margin - 29.76%
Return on average assets 8.43% 13.45%
Return on average equity 16.20% 28.92%
Employees 39,235 -
CDP Score - 86 B

Address

Lilly Corporate Center
INDIANAPOLIS, IN 46285
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Eli Lilly and Company, discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold in approximately 130 countries. The Company�s products include neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceuticals. The Company�s new molecular entities (NMEs) are in Phase III clinical trial testing include Dulaglutide, Edivoxetine, Empagliflozin-BI10773, Enzastaurin, Ixekizumab, Necitumumab,, New insulin glargine product, Novel basal insulin analog, Pomaglumetad Methionil, Ramucirumab, Solanezumab and Tabalumab. In July 2014, Anthera Pharmaceuticals Inc acquired Sollpura (liprotamase), a investigational Pancreatic Enzyme Replacement Therapy (PERT) from Eli Lilly and Company.

Officers and directors

John C. Lechleiter Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Derica W. Rice Chief Financial Officer, Executive Vice President - Global Services
Age: 49
Bio & Compensation  - Reuters
Maria A. Crowe President - Manufacturing Operations
Age: 54
Bio & Compensation  - Reuters
Jan M. Lundberg Ph.D. Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Age: 60
Bio & Compensation  - Reuters
Melissa S. Barnes Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Age: 45
Bio & Compensation  - Reuters
Michael J. Harrington Senior Vice President, General Counsel
Age: 51
Bio & Compensation  - Reuters
Stephen F. Fry Senior Vice President - Human Resources and Diversity
Age: 48
Bio & Compensation  - Reuters
Enrique A. Conterno Senior Vice President and President - Lilly Diabetes
Age: 47
Bio & Compensation  - Reuters
Susan Mahony Ph.D. Senior Vice President and President - Lilly Oncology
Age: 49
Bio & Compensation  - Reuters
Barton R. Peterson Senior Vice President - Corporate Affairs and Communications
Age: 55
Bio & Compensation  - Reuters